Sigma Planning Corp raised its stake in Cue Biopharma, Inc. (NASDAQ:CUE – Free Report) by 11.4% in the 4th quarter, HoldingsChannel reports. The firm owned 447,175 shares of the company’s stock after acquiring an additional 45,850 shares during the quarter. Sigma Planning Corp’s holdings in Cue Biopharma were worth $487,000 as of its most recent SEC filing.
Separately, Geode Capital Management LLC increased its position in shares of Cue Biopharma by 3.3% during the third quarter. Geode Capital Management LLC now owns 508,827 shares of the company’s stock worth $385,000 after acquiring an additional 16,371 shares in the last quarter. Institutional investors own 35.04% of the company’s stock.
Cue Biopharma Trading Down 5.3 %
NASDAQ:CUE opened at $1.24 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.22 and a quick ratio of 2.22. The firm has a 50-day moving average of $1.31 and a 200-day moving average of $1.13. The company has a market cap of $78.55 million, a PE ratio of -1.38 and a beta of 1.66. Cue Biopharma, Inc. has a one year low of $0.45 and a one year high of $2.36.
Insider Transactions at Cue Biopharma
About Cue Biopharma
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Further Reading
- Five stocks we like better than Cue Biopharma
- How to Invest in the FAANG Stocks
- Volatility Is Back: 3 Stocks To Cushion the S&P 500’s Swings
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- 2 Catalysts That Could Push NVIDIA Stock Up 30% This Year
- Best Stocks Under $5.00
- Do GM Stock Buybacks Make the Stock Buyable For Investors?
Want to see what other hedge funds are holding CUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cue Biopharma, Inc. (NASDAQ:CUE – Free Report).
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.